Lundbeck

News

Lundbeck names Tarek Samad to replace its retiring R&D chief, Johan Luthman, and he is facing a tough task as the firm heads towards a patent cliff.

News

Lundbeck has reported positive trial results with Cushing's therapy asedebart, a key R&D prospect as it faces a patent cliff in the next few years.

News

Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.

News

Lundbeck has appointed Markus Kede to the newly created role of chief AI officer, charged with driving its ambition to become a 'bionic' company.

News

Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

News

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.